Reuters |
AstraZeneca asthma drug hits goal, to enter competitive market
Reuters L) drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a potential $2 billion-a-year seller. Benralizumab, which is likely to … AstraZeneca: Asthma drug trial results positive Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe Asthma TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial Results |
View full post on asthma – Google News